blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2432769

EP2432769 - N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR [Right-click to bookmark this link]
Former [2012/13]N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR& xA;
[2014/43]
StatusNo opposition filed within time limit
Status updated on  05.02.2016
Database last updated on 07.10.2024
Most recent event   Tooltip22.06.2018Lapse of the patent in a contracting state
New state(s): MK		published on 25.07.2018  [2018/30]
Applicant(s)For all designated states
AbbVie Deutschland GmbH & Co KG
Max-Planck-Ring 2a
65205 Wiesbaden / DE
For all designated states
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064 / US
[2013/42]
Former [2013/24]For all designated states
Abbott GmbH & Co. KG
Max-Planck-Ring 2
65205 Wiesbaden / DE
For all designated states
AbbVie Inc.
1 North Waukegan Road
North Chicago, IL 60064 / US
Former [2012/13]For all designated states
Abbott GmbH & Co. KG
Max-Planck-Ring 2
65205 Wiesbaden / DE
For all designated states
Abbott Laboratories
100 Abbott Park Rd.
Abbott Park, IL 60064 / US
Inventor(s)01 / HAUPT, Andreas
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
02 / POHLKI, Frauke
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
03 / DRESCHER, Karla
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
04 / WICKE, Karsten
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
05 / UNGER, Liliane
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
06 / RELO, Ana-Lucia
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
07 / BESPALOV, Anton
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
08 / VOGG, Barbara
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
09 / BACKFISCH, Gisela
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
10 / DELZER, Juergen
AbbVie Deutschland GmbH & Co. KG
Knollstrasse 50
67061 Ludwigshafen / DE
11 / ZHANG, Min
AbbVie Inc.
1 North Waukegen Road
North Chicago Illinois 60064 / US
12 / LAO, Yanbin
AbbVie Inc.
1 North Waukegen Road
North Chicago Illinois 60064 / US
 [2014/35]
Former [2012/13]01 / HAUPT, Andreas
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
02 / POHLKI, Frauke
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
03 / DRESCHER, Karla
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
04 / WICKE, Karsten
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
05 / UNGER, Liliane
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
06 / RELO, Ana-Lucia
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
07 / BESPALOV, Anton
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
08 / VOGG, Barbara
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
09 / BACKFISCH, Gisela
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
10 / DELZER, Juergen
Abbott GmbH&Co. KG
Knollstr. 50
67061 Ludwigshafen / DE
11 / ZHANG, Min
Abbott Laboratories
100 Abbott Park Road
Abbott Park
Illinois 60064-6050 / US
12 / LAO, Yanbin
Abbott Laboratories
100 Abbott Park Road
Abbott Park
Illinois 60064-6050 / US
Representative(s)Reitstötter Kinzebach
Patentanwälte
Im Zollhof 1
67061 Ludwigshafen / DE
[2015/14]
Former [2012/13]Reitstötter - Kinzebach
Patentanwälte Ludwigsplatz 4
67059 Ludwigshafen / DE
Application number, filing date10719748.529.04.2010
WO2010EP55789
Priority number, dateUS20090174054P30.04.2009         Original published format: US 174054 P
[2012/13]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2010125134
Date:04.11.2010
Language:EN
[2010/44]
Type: A1 Application with search report 
No.:EP2432769
Date:28.03.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 04.11.2010 takes the place of the publication of the European patent application.
[2012/13]
Type: B1 Patent specification 
No.:EP2432769
Date:01.04.2015
Language:EN
[2015/14]
Search report(s)International search report - published on:EP04.11.2010
ClassificationIPC:C07D241/04, C07D317/06, C07D295/096, A61K31/495, A61P25/18, A61P25/28, A61P25/30
[2012/13]
CPC:
C07D295/096 (EP,US); A61P25/00 (EP); A61P25/18 (EP);
A61P25/28 (EP); A61P25/30 (EP); A61P3/04 (EP);
C07D241/04 (EP,US); C07D243/08 (EP,US); C07D317/46 (EP,US) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/13]
Extension statesRS28.11.2011
TitleGerman:N-PHENYL-(PIPERAZINYL- ODER HOMOPIPERAZINYL)-BENZOLSULFONAMID- ODER BENZOLSULFONYL-PHENYL-(PIPERAZIN- ODER HOMOPIPERAZIN) -VERBINDUNGEN ZUR BEHANDLUNG VON AUF SEROTONIN-5-HT6-REZEPTORMODULATION ANSPRECHENDEN ERKRANKUNGEN[2012/13]
English:N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR[2014/43]
French:COMPOSÉS N-PHÉNYL-(PIPÉRAZINYL OU HOMOPIPÉRAZINYL)- BENZÈNESULFONAMIDE OU BENZÈNESULFONYL-PHÉNYL-(PIPÉRAZINE OU HOMOPIPÉRAZINE) ADAPTÉS AU TRAITEMENT DE TROUBLES RÉPONDANT À LA MODULATION DU RÉCEPTEUR 5-HT6 DE LA SÉROTONINE[2012/13]
Former [2012/13]N-PHENYL-(PIPERAZINYL OR HOMOPIPERAZINYL)-BENZENESULFONAMIDE OR BENZENESULFONYL-PHENYL-(PIPERAZINE OR HOMOPIPERAZINE) COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5-HT6 RECEPTOR& xA;
Entry into regional phase28.11.2011National basic fee paid 
28.11.2011Designation fee(s) paid 
28.11.2011Examination fee paid 
Examination procedure28.11.2011Amendment by applicant (claims and/or description)
28.11.2011Examination requested  [2012/13]
06.02.2013Despatch of a communication from the examining division (Time limit: M10)
13.12.2013Reply to a communication from the examining division
21.05.2014Communication of intention to grant the patent
25.09.2014Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
15.10.2014Communication of intention to grant the patent
18.02.2015Fee for grant paid
18.02.2015Fee for publishing/printing paid
18.02.2015Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  06.02.2013
Opposition(s)05.01.2016No opposition filed within time limit [2016/10]
Fees paidRenewal fee
21.03.2012Renewal fee patent year 03
26.03.2013Renewal fee patent year 04
26.03.2014Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU29.04.2010
AT01.04.2015
BE01.04.2015
BG01.04.2015
CY01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
MK01.04.2015
MT01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SE01.04.2015
SI01.04.2015
SK01.04.2015
SM01.04.2015
TR01.04.2015
IE29.04.2015
LU29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
[2018/30]
Former [2018/02]HU29.04.2010
AT01.04.2015
BE01.04.2015
BG01.04.2015
CY01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
MT01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SE01.04.2015
SI01.04.2015
SK01.04.2015
SM01.04.2015
TR01.04.2015
IE29.04.2015
LU29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2017/38]HU29.04.2010
AT01.04.2015
BE01.04.2015
BG01.04.2015
CY01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
MT01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SE01.04.2015
SI01.04.2015
SK01.04.2015
SM01.04.2015
TR01.04.2015
IE29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2017/03]AT01.04.2015
BE01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
MT01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SI01.04.2015
SK01.04.2015
IE29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/37]AT01.04.2015
BE01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SI01.04.2015
SK01.04.2015
IE29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/24]AT01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SI01.04.2015
SK01.04.2015
IE29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/20]AT01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SK01.04.2015
IE29.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/10]AT01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
PL01.04.2015
RO01.04.2015
SK01.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/09]AT01.04.2015
CZ01.04.2015
DK01.04.2015
EE01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/07]AT01.04.2015
CZ01.04.2015
DK01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2016/06]AT01.04.2015
CZ01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
MC01.04.2015
NL01.04.2015
CH30.04.2015
LI30.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2015/51]AT01.04.2015
CZ01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
NL01.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2015/50]CZ01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
NL01.04.2015
NO01.07.2015
GR02.07.2015
IS01.08.2015
PT03.08.2015
Former [2015/49]CZ01.04.2015
FI01.04.2015
HR01.04.2015
LT01.04.2015
LV01.04.2015
NL01.04.2015
NO01.07.2015
GR02.07.2015
PT03.08.2015
Former [2015/42]NL01.04.2015
Cited inInternational search[ID]WO9902502  (SMITHKLINE BEECHAM PLC [GB], et al) [ID] 1-37 * claims 1,8,10 * * page 10, lines 27-35 *;
 [I]US2003069254  (BERGER JACOB [US], et al) [I] 1-37* claims 1,21,24 *
by applicant   - A. MENESES, DRUG NEWS PERSPECT, (2001), vol. 14, no. 7, pages 396 - 400
    - J. PHARMACOL. SCI., (2006), vol. 101, no. 1, page 124
    - EUROPEAN J. ORG. CHEM., (2002), pages 2094 - 2108
    - TETRAHEDRON, (2001), vol. 57, no. 27, pages 5885 - 5895
    - BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2000), vol. 10, no. 8, pages 835 - 838
    - SYNTHESIS, (2000), pages 103 - 108
    - TETRAHEDRON, (2000), vol. 56, no. 38, pages 7553 - 7560
    - SYNLETT., (2000), pages 475 - 480
    - ONO ET AL., CHEM. IND. (LONDON), (1983), page 480
    - LALANCETTE ET AL., CAN. J. CHEM., (1971), vol. 49, page 2990
    - BIOORGANIC AND MEDICINAL CHEMISTRY LETTERS, (2002), vol. 12, no. 15, pages 1917 - 1919
    - J. MED. CHEM., (2002), vol. 45, no. 21, pages 4679 - 4688
    - TETRAHEDRON, (2001), vol. 57, pages 9199 - 9225
    - ANALYTICAL BIOCHEMISTRY, (1980), vol. 107, pages 220 - 239
    - MUNSON; RODBARD, ANAL. BIOCHEM., (1980), vol. 107, pages 220 - 239
    - FELDMAN, ANAL. BIOCHEM., (1972), vol. 48, pages 317 - 338
    - CHENG; PRUSOFF, BIOCHEM. PHARMACOL., (1973), vol. 22, pages 2099 - 2108
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.